This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MNTA Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Momenta Pharmaceuticals Stock (NASDAQ:MNTA) 30 days 90 days 365 days Advanced Chart Get MNTA alerts:Sign Up Key Stats Today's Range$52.48▼$52.4850-Day Range$52.26▼$52.4952-Week Range$12.21▼$52.53VolumeN/AAverage Volume1.94 million shsMarket Capitalization$6.25 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Read More Receive MNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNTA Stock News HeadlinesJohnson & Johnson Files for First FDA OK of NipocalimabAugust 31, 2024 | marketwatch.comGenoptix, Momenta Shares Headed for GainsFebruary 28, 2023 | thestreet.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 30 at 2:00 AM | Brownstone Research (Ad)Johnson & Johnson, Momenta Pharma file lawsuit against Natco, Mylan in USMay 25, 2022 | msn.comEastman Kodak, Rambus: After-Hours TradingApril 30, 2022 | thestreet.comMomenta Pharmaceuticals, Inc. Common Stock (MNTA)August 3, 2021 | nasdaq.comSee More Headlines MNTA Stock Analysis - Frequently Asked Questions How were Momenta Pharmaceuticals' earnings last quarter? Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company earned $6.61 million during the quarter, compared to the consensus estimate of $5.84 million. Momenta Pharmaceuticals had a negative net margin of 757.61% and a negative trailing twelve-month return on equity of 61.44%. What other stocks do shareholders of Momenta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Momenta Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Exelixis (EXEL), Gilead Sciences (GILD), Novavax (NVAX), Bristol Myers Squibb (BMY) and Shopify (SHOP). Company Calendar Last Earnings8/10/2020Today8/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:MNTA CIK1235010 Webwww.momentapharma.com Phone617-491-9700FaxN/AEmployees131Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$290.05 million Net Margins-757.61% Pretax MarginN/A Return on Equity-61.44% Return on Assets-45.28% Debt Debt-to-Equity RatioN/A Current Ratio6.38 Quick Ratio6.38 Sales & Book Value Annual Sales$23.87 million Price / Sales261.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book11.43Miscellaneous Outstanding Shares119,029,000Free FloatN/AMarket Cap$6.25 billion OptionableOptionable Beta1.71 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MNTA) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Momenta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Momenta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
